The 12 closest competitors and alternatives to Seraxis Holdings, Inc. — ranked by similarity to what Seraxis Holdings, Inc. actually does, not by market-cap band.
Subscribe to see Seraxis Holdings, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Seraxis Holdings, Inc. is a private United States company that announced a merger in September 2026 to form a diabetes-focused biotech company.
Seraxis Holdings, Inc. is a company headquartered in United States. It has raised at least $24M across the 2 funding rounds on record. Its most recent funding round raised $10M in September 2026. Xcout tracks 3 named people at Seraxis Holdings, Inc., including Carole Welsch (Executive Officer).
At least $24M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $10M | — | |
| SEC Form D filing | $14M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to Seraxis Holdings, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Close match by what they do
Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing cell therapies for the treatment of diabetes.
Biotechnology
Paulex Bio Inc. is a biotechnology company headquartered in San Diego, California, focused on transformative treatments for type 1 and type 2 diabetes. Its lead approach targets beta cell regeneration through an oral administration.
Biotechnology
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Close match by what they do
Metabolics Pharma, Inc. is a private pharmaceutical company based in Pennsylvania, United States, focusing on drug pipelines, patents, and clinical development for diabetes.
Close match by what they do
Bigfoot Biomedical is a medical technology company headquartered in Milpitas, California, taking an unconventional approach to diabetes management.
Close match by what they do
Koligo Therapeutics Ltd is a biotechnology company based in Australia that is focused on treating chronic pancreatitis and Type 1 Diabetes.
Close match by what they do
Serendipity Ridge, LLC is a United States-based company that reported a private placement funding event on September 9, 2026.
Biotech
Terrestrial Bio, Inc. develops the Tacterra microarray patch platform to deliver next-generation therapies, such as GLP-1, through the skin using dissolvable biomaterial tips. The technology eliminates the need for needles and refrigeration, enabling patients to self-administer treatments pain-free at home or on the go.
Biotechnology
Caspian Therapeutics is a biopharmaceutical company developing menin inhibitors, such as its lead candidate KO-7246, as potential treatments for diabetes and other chronic metabolic diseases. The company focuses on a disease-modifying approach designed to restore the body's insulin-producing capacity through the expansion and enhanced function of pancreatic beta cells.
Close match by what they do
Bonside Series LLC - Series 168 is a United States-based company that engaged in a private placement (Form D) funding event on September 30, 2026.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Seraxis Holdings, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →